Liquidia Technologies

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using the company's proprietary PRINT? technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company is focused on the development of two product candidates for which they hold worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension, or PAH, and LIQ865 for the treatment of local post-operative pain.
  • TickerLQDA
  • ISINUS53635D2027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology

Analysts

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

Liana Moussatos ...
  • Shveta Dighe

Q1 Financials; On-track to Submit LIQ865/PAH NDA by YE

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ValuEngine Rating and Forecast Report for LQDA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch